Tian Hong, Zhou Shu-yun
Ai Zheng. 2002 Aug;21(8):896-9.
BACKGROUND & OBJECTIVE: This study was designed to evaluate the effectiveness of high-dose chemotherapy plus single daily dose of 250 micrograms/d rhG-CSF(lenograstim) in autologous peripheral blood stem cells mobilization and hematopoietic reconstitution after transplantation.
The study included a group of 55 consecutive patients with hematological malignancies (28 cases of acute myelogenous leukemia, 9 cases of acute lymphoblastic leukemia, 14 cases of non-Hodgkin's lymphoma, 4 cases of other disease) from October 1999 to December 2001 undergoing either EA or other intensive chemotherapies as CTX, G-CSF mobilization began from the day when the WBC count reached nadir until the day of apheresis, then after stem cell reinfusion G-CSF support was given on day +3 until neutrophil recovery. The dose of G-CSF both in mobilization and recovery support was 250 micrograms/d s.c. despite the body weight of patients.
The average time of G-CSF administrating as a mobilizing reagent was 7.12 days(range 3-14 days), and the mean time of interval from the beginning of chemotherapy to apheresis was 18.08 +/- 3.63 days. All patients need an average of 1.3 times for apheresis. The median mononuclear cell and CD34+ cell yield were 4.09 x 10(8)/kg and 8.5 x 10(6)/kg, respectively. G-CSF was used after transplantation for a median time of 8 days(range 4-19). All patients achieved an ANC > 0.5 x 10(9)/L after a median of 10.5 days (range 8-26). No severe toxic reaction was observed.
We concluded that chemotherapy plus rhG-CSF(lenograstim) given in the single dose fashion can be used in both mobilizing and post transplantation setting with satisfying outcome.
本研究旨在评估大剂量化疗加每日单次剂量250微克/天的重组人粒细胞集落刺激因子（来格司亭）在自体外周血干细胞动员及移植后造血重建中的有效性。
该研究纳入了1999年10月至2001年12月期间连续的55例血液系统恶性肿瘤患者（急性髓性白血病28例、急性淋巴细胞白血病9例、非霍奇金淋巴瘤14例、其他疾病4例），这些患者接受EA或其他强化化疗如环磷酰胺，当白细胞计数达到最低点之日起开始使用G-CSF动员，直至采集干细胞之日，然后在干细胞回输后第3天给予G-CSF支持，直至中性粒细胞恢复。无论患者体重如何，G-CSF在动员及恢复支持中的剂量均为250微克/天皮下注射。
作为动员剂使用G-CSF的平均时间为7.12天（范围3 - 14天），从化疗开始至采集干细胞期间的平均间隔时间为18.08±3.63天。所有患者平均需要采集1.3次。单个核细胞和CD34+细胞产量的中位数分别为4.09×10⁸/kg和8.5×10⁶/kg。移植后使用G-CSF的中位时间为8天（范围4 - 19天）。所有患者在中位数10.5天（范围8 - 26天）后中性粒细胞绝对值均>0.5×10⁹/L。未观察到严重的毒性反应。
我们得出结论，化疗加单剂量的重组人粒细胞集落刺激因子（来格司亭）可用于动员及移植后阶段，效果令人满意。
